June 6, 2025 Release Highlights Copied

06/06/20252025 VBCRelease note

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard will be updated to reflect the below refinement(s):

Measure Description Practice Impact
MIPS 457: Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days Denominator:

  • Added new Cancer Diagnosis ICD-10 codes and removed some Cancer Diagnosis ICD-10 codes
 Minimal shift in denominator and/or numerator count
PIMSH 9: Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) Denominator:

  • Added new Cancer Diagnosis ICD-10 codes and removed some Cancer Diagnosis ICD-10 codes
  • Telehealth Modifiers added: GT, GQ and POS 02
 Minimal shift in denominator and/or numerator count
PIMSH 10: Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs Numerator:

  • Additional Hepatitis B panel testing added

Denominator:

  • Telehealth Modifiers added: (including but not limited to) GQ, GT and POS 02
 Minimal shift in denominator and/or numerator count

Status of Dashboard Updates for 2025

CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.

Measure Description
MIPS Quality Measures Dashboard
MIPS #001 Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure)
MIPS #047 Advance Care Plan
MIPS #130 Current Medications Documentation
MIPS #226 Tobacco Screening and Cessation
MIPS #236 Controlling High Blood Pressure
MIPS #238 Use of High-Risk Medications in Older Adults (Inverse Measure)
MIPS #374 Closing the Referral Loop
MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) III Her2 Positive Breast Cancer
MIPS #451 RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy
MIPS #453 Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)
MIPS #457 Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days
MIPS #462 Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
MIPS #487 Screening for Social Drivers of Health
PIMSH #1 Advance Care Planning in Metastatic Disease
PIMSH #9 Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH #10 Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs
PIMSH #13 Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy
PIMSH #15 Antiemetic Therapy for Low-and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH #16 Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center